Steven Elliot Kauder

USPTO Granted Patents = 9 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 7.0

ph-index = 4

Forward Citations = 49(Granted Patents)

Location History:

South San Francisco, CA (US) (2017)
San Mateo, CA (US) (2018 - 2023)

Company Filing History:

Constellation Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404340 - Antibodies against signal-regulatory protein alpha and methods of use (2025-09-02),

2. 11639376 - Constructs having a SIRP-α domain or variant thereof (2023-05-02),

3. 11401338 - Antibodies against signal-regulatory protein alpha and methods of use (2022-08-02),

4. 11242404 - Antibodies against signal-regulatory protein alpha and methods of use (2022-02-08),

5. 11208459 - Constructs having a SIRP-alpha domain or variant thereof (2021-12-28),

6. 10696730 - Constructs having a SIRP-alpha domain or variant thereof (2020-06-30),

7. 10259859 - Constructs having a SIRP-α domain or variant thereof (2019-04-16),

8. 10005848 - Method of reducing blood glucose by administering RON agonists (2018-06-26),

9. 9763922 - Therapeutic compounds and uses thereof (2017-09-19),

Title: The Innovative Contributions of Steven Elliot Kauder

Introduction

Steven Elliot Kauder is a prominent inventor based in San Mateo, California, who has made significant advancements in the field of biotechnology. With a remarkable portfolio of 9 patents, his work primarily focuses on developing antibodies and polypeptides with potential applications in cancer treatment and immunology.

Latest Patents

Among his latest patents, Kauder has developed isolated antibodies that target signal-regulatory protein alpha (SIRP-α). Specifically, he has created antibodies that bind to various extracellular domains of human SIRP-α polypeptides. These antibodies can block or alter the binding interactions between SIRP-α and human CD47 polypeptides, a critical mechanism in immune response regulation. Additionally, he has designed constructs featuring high-affinity SIRP-α D1 domains that enhance phagocytosis and target harmful immune cells, showcasing a potential therapeutic route for treating cancer.

Career Highlights

Throughout his career, Steven has contributed to various esteemed organizations, including Alx Oncology Inc. and Genentech, Inc. His expertise and research have laid the groundwork for innovative therapeutic strategies that address complex diseases such as cancer.

Collaborations

Kauder's work is often complemented by collaborations with notable colleagues, including Bang Janet Sim and Hong Wan. These professional partnerships highlight the collaborative nature of scientific research, fostering the exchange of ideas and expertise to drive innovation forward.

Conclusion

Steven Elliot Kauder's contributions to biotechnology and his innovative approach to developing antibodies and polypeptides illustrate the importance of continual research and development in the fight against diseases. His patents serve as a testament to his dedication and impact within the scientific community, promising advancements in cancer treatment and immunology.

This text is generated by artificial intelligence and may not be accurate.